

September 10, 2025

To,  
Listing/ Compliance Department  
**National Stock Exchange of India Limited**  
"Exchange Plaza", Plot No. C/1,  
G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**SYMBOL: AARTIPHARM**

**Sub: Reply to query raised regarding Figures of Standalone EPS in XBRL not matching with PDF.**

Dear Sir/Madam,

This is with reference to your query dated September 08, 2025, vide email, regarding the mismatch in the figures of Standalone Earnings Per Share (EPS) in the XBRL filing and the PDF version of the financials submitted for the quarter ended June 30, 2025, on August 12, 2025.

We would like to clarify that there was an inadvertent clerical error in the XBRL submission wherein the EPS was incorrectly reported under "Earnings per equity share for discontinued operations" instead of "Earnings per equity share for continued operations."

Please note that the EPS figure of ₹5.65 pertains to continued operations and is correctly presented in the PDF version of the financials.

We regret the error and will ensure greater diligence in future submissions to avoid such discrepancies.


Thank you for bringing this to our attention.

We trust the above clarifies the position.

Kindly take the same on your record.

Thanking you,  
Yours faithfully,

For AARTI PHARMALABS LIMITED

  
10/09/2025  
**JEEVAN MONDKAR**  
COMPANY SECRETARY AND LEGAL HEAD  
ICSI M. NO. A22565



September 19, 2025

To,  
Listing/ Compliance Department  
**National Stock Exchange of India Limited**  
"Exchange Plaza", Plot No. C/1,  
G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**SYMBOL: AARTIPHARM**

**Sub: Reply to query raised regarding Figures of  
Standalone EPS in XBRL not matching with PDF.**

Dear Sir/Madam,

This is with reference to your query dated September 08, 2025, vide email, regarding the mismatch in the figures of Standalone Earnings Per Share (EPS) in the XBRL filing and the PDF version of the financials submitted for the quarter ended June 30, 2025, on August 12, 2025.

We would like to clarify that there was an inadvertent clerical error in the XBRL submission wherein the EPS was incorrectly reported under "Earnings per equity share for discontinued operations" instead of "Earnings per equity share for continued operations."

We have since rectified the error and uploaded the revised XBRL filing on September 19, 2025, correctly classifying the EPS figure under "Earnings per equity share for continued operations."

We regret the error and sincerely apologize for any inconvenience caused. We are taking steps to ensure greater diligence in future submissions to prevent such discrepancies.


Thank you for bringing this to our attention.

We trust the above clarifies the position.

Kindly take the same on your record.

Thanking you,  
Yours faithfully,

**For AARTI PHARMALABS LIMITED**

  
**JEEVAN MONDKAR**  
**COMPANY SECRETARY AND LEGAL HEAD**  
**ICSI M. NO. A22565**





Investor Relations Aarti Pharmalabs <investorrelations@aartipharmalabs.com>

---

## Integrated Filing- Financcails Submitted by Aarti Pharmalabs Limited

---

neaps@nse.co.in <neaps@nse.co.in>  
To: investorrelations@aartipharmalabs.com

Fri, Sep 19, 2025 at 6:59 PM

Dear Sir/Madam,

Thanks for filing through NSEs Electronic Application Processing System (NEAPS). The Exchange has received the submission for Integrated Filing- Financcails 19-SEP-2025.

Regards,  
National Stock Exchange of India Limited.  
Listing Compliance  
Direct No. 2659 8458/8235/8236